Cross-sectional study shows elevated TNF-α and IFN-γ linked to higher disease severity in Parkinson's disease, suggesting biomarker potential.
Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, neuroinflammation, and oxidative stress. Pro-inflammatory cytokines such as TNF-α and IFN-γ contribute to neuronal injury, whereas uric acid acts as an important endogenous antioxidant. The interaction between inflammatory cytokines and antioxidant status in PD remains incompletely understood. Methods This hospital-based cross-sectional observational study included 44 patients with clinically diagnosed PD. Disease severity was assessed using the Webster Rating Scale (WRS) and the Hoehn and Yahr (H&Y) staging system. Serum uric acid levels were estimated using the uricase-peroxidase method. Peripheral blood TNF-α and IFN-γ gene expression levels were quantified using quantitative real-time polymerase chain reaction (qRT-PCR) and analyzed using the 2^-ΔΔCt method. Correlation analysis and logistic regression were performed to evaluate associations between biomarkers and disease severity. Results The mean age of participants was 73.16 ± 8.80 years, with a male predominance of 29 (65.9%). TNF-α and IFN-γ expression levels progressively increased with advancing disease severity among patients with PD. Both cytokines demonstrated significant positive correlations with WRS and H&Y scores. In contrast, serum uric acid levels progressively declined with increasing disease severity and showed significant inverse correlations with TNF-α and IFN-γ expression. On multivariate logistic regression analysis, elevated TNF-α and IFN-γ expression remained independently associated with advanced disease severity, whereas higher serum uric acid levels demonstrated a protective association. Conclusion Higher TNF-α and IFN-γ expression, along with lower serum uric acid levels, were associated with greater disease severity. These findings suggest their potential utility as candidate biomarkers, which require validation in larger longitudinal studies.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: